KemPharm - KMPH Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KMPH shares.
View KMPH analyst ratings or view top-rated stocks.

4 analysts have issued 12-month target prices for KemPharm's stock. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $17.25 in the next twelve months. This suggests a possible upside of 218.3% from the stock's current price.
View analysts price targets for KMPH or view top-rated stocks among Wall Street analysts.

KemPharm's stock was trading at $4.59 on January 1st, 2023. Since then, KMPH stock has increased by 18.1% and is now trading at $5.42.
View the best growth stocks for 2023 here.

KemPharm saw a drop in short interest in January. As of January 15th, there was short interest totaling 1,370,000 shares, a drop of 16.0% from the December 31st total of 1,630,000 shares. Based on an average daily volume of 237,400 shares, the short-interest ratio is currently 5.8 days. Approximately 4.4% of the company's stock are sold short.
View KemPharm's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our KMPH earnings forecast.

KemPharm, Inc. (NASDAQ:KMPH) posted its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The specialty pharmaceutical company earned $2.87 million during the quarter, compared to analyst estimates of $2.97 million. KemPharm had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

Based on aggregate information from My MarketBeat watchlists, some companies that other KemPharm investors own include Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), BioCryst Pharmaceuticals (BCRX), Cara Therapeutics (CARA), DURECT (DRRX) and Paratek Pharmaceuticals (PRTK).

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

Shares of KMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KMPH stock can currently be purchased for approximately $5.42.

KemPharm (NASDAQ:KMPH) has a market capitalization of $187.02 million and generates $10.72 million in revenue each year.

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.